Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
African American Antiplatelet Stroke Prevention Study
NCT00004727Phase 4Completed
- Sponsor
- National Institute of Neurological Disorders and Stroke
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of ticlopidine in ischemic stroke (2 arms), sponsored by National Institute of Neurological Disorders and Stroke. Primary endpoint: Composite endpoint of recurrent stroke, myocardial infarction, and vascular death at 2 years. Status: completed.
02
Drugs
ticlopidine
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT00004727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004727.